secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0000950170-24-007941
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics signs $20M ATM equity offering with Cantor Fitzgerald
-------------------------------------------------------------------------

- ATM agreement allows sale of up to $20M of common stock through Cantor as sales agent.
- Agent will receive 3.0% of gross proceeds per sale; no minimum obligation to sell.
- Net proceeds to fund pipeline development and general corporate/working capital.
- Agreement is terminable by either party on ten days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024007941/0000950170-24-007941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024007941/sabs-20240126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-007941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer